Company profile
INTEGRA LIFESCIENCES HOLDINGS CORP
NASDAQ:IARTMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACLERASTIDE | phase3 | — | 2 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02482948 | — | terminated | 2015-06-01 | 2017-03-01 | Integra LifeSciences Corporation | MEDIHONEY® Gel Versus Collagenase for Wound Debridement |
| NCT01840085 | phase3 | terminated | 2015-12-01 | 2015-12-01 | Integra LifeSciences Corporation | Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use |
| NCT01849965 | phase3 | terminated | 2013-04-01 | 2015-12-01 | Integra LifeSciences Corporation | Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers |
| NCT01830348 | phase3 | terminated | 2013-02-01 | 2015-12-01 | Integra LifeSciences Corporation | Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers |
FDA applications (0)
No records yet.